Paul Badawi, Founder and CEO of Sight Sciences and Leon Herndon, MD, Duke University Eye Center, Durham, NC, commented on the ...

Prospective study data and retrospective registry data were analyzed in the manuscripts recently published by the Journal of ...

Canaloplasty has emerged as a viable surgical intervention for the management of open-angle glaucoma, offering an alternative to traditional procedures such as trabeculectomy. This non-penetrating ...

Primary open-angle glaucoma (POAG) is among the leading causes of irreversible blindness. Early detection and treatment are crucial for vision preservation, and research to identify genes associated ...

University of Missouri researchers have discovered two potential biomarkers of glaucoma – agmatine and thiamine ...

Avisi Technologies has released positive 12-month clinical data on the VisiPlate Aqueous Shunt from the VITA Trial. The VITA ...

Elevated systolic blood pressure (BP) and pulse pressure were associated with an increased risk of incident primary open-angle glaucoma. There was no significant association between diastolic BP and ...

SpyGlass Pharma reports positive 36-month first-in-human and 3-month phase I/II trial results for its novel BIM-IOL System: Aliso Viejo, California Wednesday, November 12, 2025, 1 ...

"OMNI continues to deliver results for patients, whether it be patients undergoing cataract surgery, those that have already had cataract surgery and are now pseudophakic, or groups at historically ...

Open-angle glaucoma represents one of the most prevalent causes of irreversible sight loss globally. The principal aim of treatment is to lower intraocular pressure (IOP) to slow the progression of ...

Trial at 36 Months: 37% reduction in mean intraocular pressure (IOP) in evaluable patients across all dose groups with 95% of patients off all topical IOP-lowering drops100% of evaluable patients ...